TG Therapeutics will showcase new BRIUMVI (ublituximab-xiiy) data at AAN 2026 in Chicago, including the first Phase 4 real-world...

Ataibeckley has cleared a key regulatory hurdle for its lead program in treatment-resistant depression, securing FDA alignment at end-of-Phase...

Atea Pharmaceuticals has completed enrollment of its North American phase 3 C-BEYOND trial evaluating the fixed-dose combination of bemnifosbuvir...

Metagenomi Therapeutics (Nasdaq: MGX) reported full-year 2025 results, unveiled a corporate rebrand, and detailed clinical readiness steps for its...

The FDA just accused a sponsor of pushing distorted data to conceal a failed gene therapy — publicly, on...

Camp4 Therapeutics reported full-year 2025 results, advanced its lead SYNGAP1 program toward first-in-human testing, secured a discovery-stage collaboration with...

BridgeBio Oncology Therapeutics reported fourth‑quarter and full‑year 2025 results and, more importantly for the market, unveiled early clinical signals...

aTyr Pharma will meet the FDA in mid-April 2026 to review mixed Phase 3 results for efzofitimod in pulmonary...

Kuva Labs has signed a definitive agreement to acquire Lisata Therapeutics via a tender offer at $5.00 per share...

UroGen Pharma has granted inducement restricted stock units to 11 new hires, covering up to 51,200 ordinary shares that...